Filter search criteria using below inputs
Click on magnifying glass icon to search
Company | Country | Symbol |
---|
Time | Volume | SMMT |
---|---|---|
09:32 ET | 23320 | 4.61 |
09:36 ET | 800 | 4.68 |
09:38 ET | 1684 | 4.69 |
09:39 ET | 3587 | 4.69 |
09:41 ET | 2895 | 4.66 |
09:45 ET | 1408 | 4.66 |
09:48 ET | 12160 | 4.665 |
09:50 ET | 2383 | 4.6599 |
09:52 ET | 200 | 4.66 |
09:54 ET | 2163 | 4.65 |
09:56 ET | 725 | 4.665 |
09:57 ET | 1600 | 4.695 |
09:59 ET | 1400 | 4.71 |
10:01 ET | 1841 | 4.71 |
10:03 ET | 1705 | 4.7 |
10:06 ET | 13741 | 4.76 |
10:08 ET | 15073 | 4.83 |
10:10 ET | 7783 | 4.81 |
10:12 ET | 22063 | 4.87 |
10:14 ET | 22676 | 4.9 |
10:15 ET | 22863 | 4.8999 |
10:17 ET | 13592 | 4.94 |
10:19 ET | 21882 | 4.955 |
10:21 ET | 14350 | 4.93 |
10:24 ET | 20143 | 5.01 |
10:26 ET | 24387 | 5.03 |
10:28 ET | 32114 | 5.06 |
10:30 ET | 15400 | 5.03 |
10:32 ET | 11505 | 5.05 |
10:33 ET | 18539 | 5.0349 |
10:35 ET | 18402 | 5.07 |
10:37 ET | 15920 | 5.06 |
10:39 ET | 16791 | 5.03 |
10:42 ET | 17455 | 4.9122 |
10:44 ET | 5786 | 4.93 |
10:46 ET | 3059 | 4.955 |
10:48 ET | 3391 | 4.935 |
10:50 ET | 107199 | 4.9 |
10:51 ET | 11405 | 4.865 |
10:53 ET | 3674 | 4.885 |
10:55 ET | 16396 | 4.84 |
10:57 ET | 1340 | 4.85 |
11:00 ET | 2400 | 4.835 |
11:02 ET | 368 | 4.85 |
11:04 ET | 1816 | 4.855 |
11:06 ET | 9097 | 4.9 |
11:08 ET | 9716 | 4.9 |
11:09 ET | 3840 | 4.89 |
11:11 ET | 800 | 4.885 |
11:13 ET | 3576 | 4.915 |
11:15 ET | 6236 | 4.92 |
11:18 ET | 535 | 4.91 |
11:20 ET | 754 | 4.92 |
11:22 ET | 500 | 4.925 |
11:24 ET | 4613 | 4.92 |
11:26 ET | 2488 | 4.925 |
11:27 ET | 13585 | 4.91 |
11:29 ET | 984 | 4.905 |
11:31 ET | 9779 | 4.885 |
11:33 ET | 3518 | 4.93 |
11:36 ET | 1350 | 4.925 |
11:38 ET | 4581 | 4.946 |
11:40 ET | 46047 | 4.92 |
11:42 ET | 2901 | 4.9 |
11:44 ET | 2750 | 4.895 |
11:45 ET | 584 | 4.905 |
11:47 ET | 1500 | 4.9 |
11:49 ET | 600 | 4.9 |
11:51 ET | 200 | 4.895 |
11:54 ET | 4769 | 4.89 |
11:56 ET | 1200 | 4.875 |
11:58 ET | 2648 | 4.874 |
12:00 ET | 2112 | 4.895 |
12:02 ET | 1413 | 4.895 |
12:03 ET | 700 | 4.905 |
12:05 ET | 5027 | 4.88 |
12:07 ET | 1950 | 4.9 |
12:09 ET | 19305 | 4.895 |
12:12 ET | 13407 | 4.87 |
12:14 ET | 7162 | 4.84 |
12:16 ET | 4421 | 4.83 |
12:18 ET | 16466 | 4.82 |
12:20 ET | 6512 | 4.815 |
12:21 ET | 5581 | 4.78 |
12:23 ET | 6005 | 4.79 |
12:25 ET | 4041 | 4.78 |
12:27 ET | 10472 | 4.775 |
12:30 ET | 3800 | 4.8 |
12:32 ET | 2200 | 4.82 |
12:34 ET | 8751 | 4.84 |
12:36 ET | 5367 | 4.86 |
12:38 ET | 3054 | 4.86 |
12:39 ET | 700 | 4.87 |
12:41 ET | 1386 | 4.87 |
12:43 ET | 15384 | 4.905 |
12:45 ET | 6074 | 4.925 |
12:48 ET | 3400 | 4.9 |
12:50 ET | 4034 | 4.9295 |
12:52 ET | 100 | 4.93 |
12:54 ET | 500 | 4.9299 |
12:56 ET | 3887 | 4.915 |
12:57 ET | 1611 | 4.925 |
12:59 ET | 700 | 4.925 |
01:01 ET | 21616 | 4.84 |
01:03 ET | 1800 | 4.87 |
01:06 ET | 2825 | 4.85 |
01:08 ET | 7512 | 4.86 |
01:10 ET | 6649 | 4.825 |
01:12 ET | 4228 | 4.84 |
01:14 ET | 800 | 4.845 |
01:15 ET | 4955 | 4.835 |
01:17 ET | 3619 | 4.845 |
01:19 ET | 11252 | 4.805 |
01:21 ET | 1600 | 4.82 |
01:24 ET | 19916 | 4.825 |
01:26 ET | 6685 | 4.78 |
01:28 ET | 7418 | 4.765 |
01:30 ET | 19347 | 4.73 |
01:32 ET | 9691 | 4.75 |
01:33 ET | 6202 | 4.72 |
01:35 ET | 8903 | 4.725 |
01:37 ET | 12056 | 4.71 |
01:39 ET | 2824 | 4.71 |
01:42 ET | 5126 | 4.7 |
01:44 ET | 2211 | 4.705 |
01:46 ET | 4634 | 4.7 |
01:48 ET | 4010 | 4.7 |
01:50 ET | 12424 | 4.705 |
01:51 ET | 18623 | 4.755 |
01:53 ET | 12895 | 4.76 |
01:55 ET | 2900 | 4.73 |
01:57 ET | 600 | 4.745 |
02:00 ET | 3452 | 4.725 |
02:02 ET | 2604 | 4.72 |
02:04 ET | 17501 | 4.77 |
02:06 ET | 844 | 4.775 |
02:08 ET | 2499 | 4.775 |
02:09 ET | 500 | 4.77 |
02:11 ET | 3634 | 4.785 |
02:13 ET | 400 | 4.785 |
02:15 ET | 200 | 4.785 |
02:18 ET | 1068 | 4.785 |
02:20 ET | 800 | 4.79 |
02:22 ET | 22837 | 4.785 |
02:24 ET | 4817 | 4.82 |
02:26 ET | 9239 | 4.82 |
02:27 ET | 100 | 4.82 |
02:31 ET | 300 | 4.83 |
02:33 ET | 1500 | 4.825 |
02:36 ET | 4729 | 4.815 |
02:38 ET | 454 | 4.815 |
02:40 ET | 1100 | 4.825 |
02:42 ET | 2402 | 4.815 |
02:45 ET | 200 | 4.81 |
02:47 ET | 1505 | 4.83 |
02:49 ET | 500 | 4.83 |
02:51 ET | 404 | 4.83 |
02:54 ET | 1408 | 4.83 |
02:56 ET | 600 | 4.825 |
02:58 ET | 13839 | 4.82 |
03:00 ET | 1500 | 4.825 |
03:02 ET | 4130 | 4.81 |
03:03 ET | 4984 | 4.805 |
03:05 ET | 2300 | 4.8 |
03:07 ET | 1200 | 4.81 |
03:09 ET | 12175 | 4.795 |
03:12 ET | 1552 | 4.7861 |
03:14 ET | 1474 | 4.795 |
03:16 ET | 800 | 4.795 |
03:18 ET | 1211 | 4.795 |
03:20 ET | 910 | 4.79 |
03:21 ET | 4284 | 4.785 |
03:23 ET | 400 | 4.79 |
03:25 ET | 1870 | 4.8 |
03:27 ET | 1100 | 4.795 |
03:30 ET | 8431 | 4.775 |
03:32 ET | 26880 | 4.78 |
03:34 ET | 13323 | 4.755 |
03:36 ET | 9141 | 4.72 |
03:38 ET | 10263 | 4.73 |
03:39 ET | 8947 | 4.73 |
03:41 ET | 7796 | 4.74 |
03:43 ET | 23091 | 4.75 |
03:45 ET | 18912 | 4.715 |
03:48 ET | 25679 | 4.72 |
03:50 ET | 32272 | 4.76 |
03:52 ET | 21599 | 4.8 |
03:54 ET | 27361 | 4.79 |
03:56 ET | 34724 | 4.77 |
03:57 ET | 42568 | 4.81 |
03:59 ET | 44379 | 4.8 |
Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
---|---|---|---|
Summit Therapeutics Inc | 3.3B | -3.1x | --- |
Biohaven Ltd | 3.1B | -6.0x | --- |
Vitaspring Biomedical Co. Ltd | 3.1B | 3,311.3x | --- |
Iovance Biotherapeutics Inc | 3.1B | -6.0x | --- |
Xenon Pharmaceuticals Inc | 3.1B | -14.9x | --- |
Apogee Therapeutics Inc | 3.0B | -30.4x | --- |
Summit Therapeutics Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of patient, physician and caregiver medicinal therapies. The Company's development candidate is ivonescimab, a potential first-in-class bispecific antibody intending to combine the effects of immunotherapy via a blockade of PD-1 with the anti-angiogenesis effects of an anti-VEGF compound into a single molecule. It develops ivonescimab in non-small cell lung cancer (NSCLC), specifically launching Phase III clinical trials in the indications such as ivonescimab combined with chemotherapy in patients with epidermal growth factor receptor (EGFR)-mutated, locally advanced or metastatic non-squamous NSCLC who have progressed after treatment with a third-generation EGFR tyrosine kinase inhibitor (HARMONi), and ivonescimab combined with chemotherapy in first-line metastatic squamous NSCLC patients (HARMONi-3). Its ivonescimab is engineered with Akeso's Tetrabody technology.
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $3.3B |
---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 702.0M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | -1.26 |
EPS | $-1.54 |
Book Value | $0.11 |
P/E Ratio | -3.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.